Obesity and Glucagon-Like Peptide-1 Receptor Agonists
Francesca Celletti, Francesco Branca, Jeremy Farrar
Abstract
This Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response to the obesity pandemic.
Topics & Concepts
MedicineGlucagon-like peptide-1ObesityGlucagon-like peptide 1 receptorReceptorPandemicGlucagonInternal medicineEndocrinologyDiabetes mellitusCoronavirus disease 2019 (COVID-19)AgonistType 2 diabetesInsulinDiseaseInfectious disease (medical specialty)Diabetes Treatment and ManagementPharmacology and Obesity TreatmentDiabetes Management and Research